Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 3, 2002, Pages 1239-1246

  Nauck, Michael A ^a,e   Heimesaat, Markus M ^a   Behle, Kai ^a   Holst, Jens J ^b   Nauck, Markus S ^c   Ritzel, Robert ^a   Hüfner, Michael ^d   Schmiegel, Wolff H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C PEPTIDE; CATECHOLAMINE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; NORADRENALIN;

ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; COGNITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; STEADY STATE;

EID: 0036959991     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.3.8355     Document Type: Article

References (55)

1. Creutzfeldt W 1979 The incretin concept today. Diabetologia 16:75-85
2. Creutzfeldt W, Nauck M 1992 Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177
3. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2:1300-1304
4. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917
5. Fehmann HC, Göke R, Göke B 1995 Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390-410
6. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
7. Nauck MA, Weber I, Bach I, Richter S, Ørskov C, Holst JJ, Schmiegel W 1998 Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2-diabetic patients. Diabet Med 15:937-945
8. Nauck MA 1997 Glucagon-like peptide 1. Curr Opin Endocrinol Diabetes 4:256-261
9. Nauck MA, Holst JJ, Willms B, Schmiegel W 1997 Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187-195
10. Nauck MA, Holst JJ, Willms B 1997 Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29:411-416
11. Schmidt WE, Siegel EG, Creutzfeldt W 1985 Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28:704-707
12. Holst JJ, Ørskov C, Vagn-Nielsen O, Schwartz TW 1987 Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174
13. Ørskov C, Holst JJ, Nielsen OV 1988 Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013
14. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S 1989 Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905
15. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ 1993 Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673
16. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
17. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
18. Creutzfeldt WO, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19:580-586
19. Boyle PJ, Shah SD, Cryer PE 1989 Insulin, glucagon and catecholamines in prevention of hypoglycaemia during fasting. Am J Physiol 256:E651-E661
20. De Feo P, Perriello G, Torlone E, Fanelli C, Ventura MM, Santeusanio F, Brunetti P, Gerich JE, Bolli GB 1991 Evidence against important catecholamine compensation for absent glucagon counterregulation. Am J Physiol 260:E203-E212
21. Cryer PE, Fisher JN, Shamoon H 1994 Hypoglycemia. Diabetes Care 17:734-755
22. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J 1991 Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction. Am J Physiol 260:E67-E74
23. Nauck MA, Behle K, Heimesaat MM, Holst JJ, Hüfner M, Schmiegel W 1999 Hypoglycaemia-counterregulation under the influence of exogenous glucagon-like peptide 1 (GLP-1). Diabetologia 42(Suppl 1):A198
24. Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Platanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich J, Bolli G 1993 Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 329:834-839
25. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
26. Nauck MA 1996 Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 13 (Suppl):S39-S43
27. Sturm W, Hartje W 1982 Störungen der intellektuellen funktionen. In: Poeck K, ed. Klinische neuropsychologie. Stuttgart: Thieme
28. Stroop JR 1935 Studies of interference in serial verbal reactions. J Exptl Psychol 18:643-662
29. Ørskov C, Holst JJ 1987 Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47:165-174
30. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539
31. DaPrada M, Zürcher G 1976 Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19:1161-1174
32. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J 1980 Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behaviour. J Clin Endocrinol Metab 51:520-528
33. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B 1986 Use of biosysnthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 77:98-105
34. Van Cauter W, Mestrez F, Sturis J, Polonsky KS 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377
35. Hovorka R, Jones RH 1994 How to measure insulin secretion. Diabetes Metab Rev 10:91-117
36. Hvidberg A, Nielsen MT, Hilsted J, Ørskov C, Holst JJ 1994 Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43:104-108
37. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W 1995 Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32:13-16
38. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR, Smith DM 1996 Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 137:4130-4138
39. Beak SA, Heath MM, Small CJ, Morgan DGA, Ghatei MA, Taylor AD, Buckingham JC, Bloom SR, Smith DM 1998 Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest 101:1334-1341
40. De Feo P, Perriello G, De Cosmo S, Ventura MM, Campbell PJ, Brunetti P, Gerich JE, Bolli GB 1986 Comparison of glucose counterregulation during short-term and prolonged hypoglycemia in normal humans. Diabetes 35:563-569
41. Minaker KL, Rowe JW, Young JB, Sparrow D, Pallotta JA, Landsberg L 1982 Effect of age on insulin stimulation of sympathetic nervous system activity in man. Metabolism 31:1181-1184
42. Ørskov C, Poulsen SS, Møller M, Holst JJ 1996 Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes 45:832-835
43. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C 1999 Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81-86
44. Flint A, Raben A, Astrup A, Holst JJ 1998 Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520
45. Tang-Christensen M, Larsen PJ, Göke R, Fink Jensen A, Jessop DS, Møller M, Sheikh SP 1996 Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856
46. Ørskov C, Wettergren A, Holst JJ 1993 Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661
47. Toft-Nielsen M, Hvidberg A, Hilsted J, Dige Petersen H, Holst JJ 1996 No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects. Diabet Med 13:544-548
48. Shalev A, Holst JJ, Keller U 1997 Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 27:10-16
49. Gromada J, Ding WG, Barg S, Renstrom E, Rorsman P 1997 Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflügers Arch 434:515-524
50. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P 1998 Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47:57-65
51. Gromada J, Holst JJ, Rorsman P 1998 Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch 435:583-594
52. Ritzel R, Ørskov C, Holst JJ, Nauck MA 1995 Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720 -725
53. Toft-Nielsen M, Madsbad S, Holst JJ 1998 Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41:1180-1186
54. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J 1995 Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cytosolic calcium levels in β TC3 cells and rat panceatic beta cells. Diabetologia 38:1025-1032
55. Nauck M 1999 Insulin secretagogues. Topic Endocrinol 11:6-10